Boston, MA 10/10/2014 (wallstreetpr) – Bio pharmaceutical firm XOMA Corp (NASDAQ:XOMA) announced yesterday that it had initiated the phase 1 study of its drug candidate XOMA 358. The tests are expected to through more light on the effects that increasing doses of XOMA 358 could have on the level of Glucose and insulin levels in […]
NASDAQ:XOMA
Why XOMA Corp (NASDAQ:XOMA) Is Unbowed By Its Series Of Disappointment
XOMA Corp (NASDAQ:XOMA) is going down if you are looking at the shares now. But there is much more to the company than the string of bad news around it. What is going on around XOMA is that investors are doing what they usually do when a stock reports below expectations. Also, the company has […]
